Minerva Neurosciences publishes presentation on roluperidone for schizophrenia negative symptoms
NERV•Minerva Neurosciences published a presentation on roluperidone for schizophrenia negative symptoms. Its confirmatory C19 trial is enrolling 380 patients, while combined C03 and C07 analyses found improvement on primary negative symptoms with 64 mg roluperidone versus placebo (p=0.031).
1. Trial and analysis findings
The confirmatory C19 trial is actively enrolling and targets 380 patients for a 12-week placebo-controlled efficacy evaluation, followed by a 52-week phase assessing safety and relapse against antipsychotics. Combined C03 and C07 analyses showed significant improvement in primary negative symptoms versus placebo with roluperidone 64 mg (p=0.031); both studies also showed statistically significant improvements in personal and social functioning at that dose.
